ArticleGastroenterology research and practice2018
Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study.
Article in Gastroenterology research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03210298 (Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy), which is not on this map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review.The oncologist · 2025Pooled it
- Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines.Cancer medicine · 2025Pooled it
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework.The British journal of surgery · 2022Pooled it
- Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.Cancers · 2022Guideline
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study.Journal of cancer research and clinical oncology · 2023Trial
- Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).Annals of surgical oncology · 2021Trial
- Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis.International journal of molecular sciences · 2026Review
- Effects of multi-electrode electrostatic precipitation during intraperitoneal aerosolized drug delivery: Insights from a large animal model.Bioengineering & translational medicine · 2026Article
- PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases.Pleura and peritoneum · 2026Article
- Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review.Pharmaceutics · 2026Review
- Review
- Pressurized intraperitoneal aerosol chemotherapy enhances cisplatin efficacy in colorectal cancer organoids.Scientific reports · 2025Article
- Peritoneal Oligometastasis in Gastric Cancer: Diagnostic Strategies, Patient Selection, and Emerging Therapeutic Approaches.Journal of gastric cancer · 2025Review
- Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives.Cancers · 2025Review
- Article
- Modified scoring system for the quantitative assessment of histological regression in peritoneal carcinomatosis after pressurized intraperitoneal aerosol chemotherapy: A pilot study.Oncology letters · 2024Article
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Gastric Cancer: Feasibility, Efficacy and Safety-A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist's perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Occupational Exposure during Intraperitoneal Pressurized Aerosol Chemotherapy Using Doxorubicin in a Pig Model.Safety and health at work · 2023Article
- Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance.Pleura and peritoneum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel drug delivery system with superior pharmacological properties for treating peritoneal metastasis (PM). Safety and efficacy results of PIPAC with cisplatin/doxorubicin or oxaliplatin from a registry cohort are presented.
methodsIRB-approved registry study. Retrospective analysis. No predefined inclusion criteria, individual therapeutic recommendation by the interdisciplinary tumor board. Safety assessment with CTCAE 4.0. Histological assessment of tumor response by an independent pathologist using the 4-tied peritoneal regression grading system (PRGS). Mean PRGS and ascites volume were assessed at each PIPAC.
resultsA total of 142 PIPAC procedures were scheduled in 71 consecutive patients with PM from gastric (
conclusionPIPAC is feasible, safe, and well-tolerated and can induce histological regression in a significant proportion of pretreated PM patients. This trial is registered with NCT03210298.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.